Compare stocks

SCHOTT Pharma AG & Co. KGaA specializes in the design and manufacture of drug containment and delivery solutions for injectable medications, including prefillable glass and polymer syringes, cartridges, vials, and ampoules. Established as a standalone entity in August 2022 following its separation from SCHOTT AG, the company is headquartered in Mainz, Germany, and operates 16 manufacturing sites across Europe, North and South America, and Asia. With a portfolio of over 1,000 patents and a dedicated R&D center in Switzerland, SCHOTT Pharma focuses on developing innovative solutions to meet the evolving needs of the pharmaceutical industry. The company serves over 1,800 customers, including the top 30 pharmaceutical manufacturers for injectable drugs, and reported revenues of €821 million in the fiscal year 2022. SCHOTT Pharma is committed to sustainable development, aiming to achieve climate neutrality by 2030.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.